| Literature DB >> 32154748 |
Chu-Chi Lin1,2, Chun-Bing Chen1,2,3,4,5,6,7, Chuang-Wei Wang1,2, Shuen-Iu Hung2, Wen-Hung Chung1,2,3,5,6,7.
Abstract
Introduction: The clinical manifestations of cutaneous adverse drug reactions are variable with different severity. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs) majorly caused by drugs and mediated by cytotoxic T cells.Areas covered: In this review, we focus on risk factors that contribute to the development of SJS/TEN and review the updated immune mechanism, preventive strategies as well as current therapeutic approaches for SJS/TEN.Expert opinion: The progress of SJS/TEN researches reveals that cytotoxic T cells majorly activated by drug interacted with the human leukocyte antigen (HLA) and T cell receptors play an important role for the immune mechanism of SJS/TEN. Several clinical assessment tools and in vitro drug-T cells activation tests have been developed to identify the causality of SJS/TEN. New therapeutic approaches and biologics such as TNF-alpha antagonist have been conducted to improve the prognosis of SJS/TEN.Entities:
Keywords: Human leukocyte antigen (HLA); Stevens-Johnson syndrome (SJS); T cell receptors; severe cutaneous adverse reactions; toxic epidermal necrolysis (TEN)
Mesh:
Substances:
Year: 2020 PMID: 32154748 DOI: 10.1080/1744666X.2020.1740591
Source DB: PubMed Journal: Expert Rev Clin Immunol ISSN: 1744-666X Impact factor: 4.473